Puma Biotechnology | PBYI - Debt


Puma Biotechnology reported $89.06M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Daiichi Sankyo JPY 300.48B 99.34B Mar/2026
Exelixis USD 165.93M 3.61M Jun/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
MacroGenics USD 36.51M 500K Mar/2026
Moderna USD 1.3B 7M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Takeda JPY 4.94T 58.13B Jun/2026
TG Therapeutics USD 754.44M 884K Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026